Sentilus was aquired by Immucor (NASDAQ: BLUD) in October of 2014. Sentilus, spun out of Duke University, and was focused to developing and commercializing non-fouling surface coatings initiated at Duke. The firm is developing an inkjet-printed antibody microarray-based technology called Femtoarrays for use in in vitro diagnostics, including transfusion diagnostics. Early efforts have been focused on developing coatings for biomedical applications, particularly for clinical diagnostic applications.
